ResMed Inc. (NYSE:RMD) insider David Pendarvis sold 4,457 shares of the firm’s stock in a transaction that occurred on Monday, February 4th. The stock was sold at an average price of $93.50, for a total value of $416,729.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Shares of RMD opened at $95.16 on Wednesday. The company has a quick ratio of 1.76, a current ratio of 2.44 and a debt-to-equity ratio of 0.61. ResMed Inc. has a 52-week low of $87.67 and a 52-week high of $118.50. The firm has a market capitalization of $13.52 billion, a price-to-earnings ratio of 26.96, a price-to-earnings-growth ratio of 2.51 and a beta of 0.54.
ResMed (NYSE:RMD) last issued its quarterly earnings data on Thursday, January 24th. The medical equipment provider reported $1.00 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.95 by $0.05. ResMed had a return on equity of 26.53% and a net margin of 18.34%. The firm had revenue of $651.10 million during the quarter, compared to the consensus estimate of $676.77 million. During the same quarter in the previous year, the company posted $1.00 EPS. The business’s revenue for the quarter was up 8.3% compared to the same quarter last year. On average, equities research analysts forecast that ResMed Inc. will post 3.55 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 14th. Shareholders of record on Thursday, February 7th will be given a $0.37 dividend. The ex-dividend date is Wednesday, February 6th. This represents a $1.48 annualized dividend and a yield of 1.56%. ResMed’s payout ratio is 41.93%.
A number of institutional investors and hedge funds have recently modified their holdings of RMD. Raymond James & Associates raised its position in ResMed by 21.4% in the 2nd quarter. Raymond James & Associates now owns 14,180 shares of the medical equipment provider’s stock valued at $1,471,000 after purchasing an additional 2,499 shares during the last quarter. Schroder Investment Management Group raised its position in ResMed by 17.9% in the 2nd quarter. Schroder Investment Management Group now owns 163,700 shares of the medical equipment provider’s stock valued at $17,038,000 after purchasing an additional 24,900 shares during the last quarter. United Services Automobile Association raised its position in ResMed by 97.5% in the 2nd quarter. United Services Automobile Association now owns 89,762 shares of the medical equipment provider’s stock valued at $9,298,000 after purchasing an additional 44,320 shares during the last quarter. Denali Advisors LLC raised its position in ResMed by 1,279.1% in the 3rd quarter. Denali Advisors LLC now owns 125,500 shares of the medical equipment provider’s stock valued at $14,475,000 after purchasing an additional 116,400 shares during the last quarter. Finally, Private Trust Co. NA bought a new position in ResMed in the 3rd quarter valued at $216,000. Hedge funds and other institutional investors own 64.87% of the company’s stock.
RMD has been the subject of several analyst reports. Deutsche Bank downgraded ResMed from a “buy” rating to a “hold” rating in a research report on Wednesday, January 23rd. JPMorgan Chase & Co. downgraded ResMed from a “neutral” rating to an “underweight” rating and set a $99.60 target price for the company. in a research report on Friday, January 25th. BMO Capital Markets upgraded ResMed from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $109.00 to $127.00 in a research report on Monday, December 10th. Goldman Sachs Group downgraded ResMed from a “buy” rating to a “neutral” rating in a research report on Friday, January 25th. Finally, Credit Suisse Group upgraded ResMed from a “neutral” rating to an “outperform” rating in a research report on Friday, October 26th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $113.20.
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.
Read More: Why do company’s buyback their stock?
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.